Enhancing the Precision and Safety of CAR Immune Cell Therapy through Tunable Biological Circuits
Neil Koby Reid Introduction. Chimeric Antigen Receptor (CAR) T-cell therapy is one branch of immunotherapy that is successful in treating refractory hematological malignancies1,2. Current CAR immune cells are host-specific cells that express transmembrane proteins that activate intrinsic immune cell pathways without the traditional MHC presentation. Newer generations of CAR therapies…